TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04732793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyruan ONE®
Description: For use as a symptomatic treatment of osteoarthritis (OA) of the knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durolane®
Description: For use as a symptomatic treatment of osteoarthritis (OA) of the knee
Study: NCT04329065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
Description: Given ID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given via infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV
Study: NCT04942067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575+ Pd
Description: APG-2575 + Pomalidomide 4mg QD x 21 days + dexamethasone (40 mg for patients ≤ 75 years old or 20 mg for patients \> 75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575 + DRd
Description: APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg for patients \> 75 years old) once weekly, and daratumumab will be administered intravenously at a dose of 16 mg/kg (or 1800 mg administered subcutaneously if commercially available) weekly in cycles 1 and 2 and then every 2 weeks in cycles 3 to 6 and every 4 weeks thereafter.
Study: NCT06399042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SP5M002 inj
Description: pre-filled syringe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synovian inj
Description: pre-filled syringe
Study: NCT05748899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ujjayi pranayama
Description: this group will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
Study: NCT05923515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000197
Description: for injection
Study: NCT05805449

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Surgery
Description: Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Description: Participants will have 40-50cc of peripheral whole blood drawn into a syringe pre-loaded with acid citrate dextrose (ACD) anticoagulant and concentrated PRP harvested by double centrifugation technique using the manufacturer's kit and benchtop centrifuge. This typically yields 5-8cc of PRP that is 18-times more concentrated than baseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Description: Participants will have 40-50cc of peripheral whole blood drawn into a syringe pre-loaded with acid citrate dextrose (ACD) anticoagulant and concentrated PRP harvested by double centrifugation technique using the manufacturer's kit and benchtop centrifuge. This typically yields 5-8cc of PRP that is 18-times more concentrated than baseline.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matrix
Description: Participants will receive 200g of paste matrix and 200g injected at the following sites: the internal opening closure site at level of the sphincter muscle, within the walls of the fistula tract along its length, and within the tissue of an advancement flap particularly at areas of tissue apposition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matrix
Description: Participants will receive 200g of paste matrix and 200g injected at the following sites: the internal opening closure site at level of the sphincter muscle, within the walls of the fistula tract along its length, and within the tissue of an advancement flap particularly at areas of tissue apposition.
Study: NCT05923515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000197
Description: for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000197
Description: for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000197
Description: for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000197
Description: for injection
Study: NCT06437756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraband resistance training
Description: Three sessions of 30 minutes each was used to complete the intervention over the course of six weeks (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session Participants were advised to take 5 mins rest before moving to next movement if they would feel fatigued after one movement. Thera-Band was utilized in only three different colors for the workouts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Resistance Training
Description: The intervention was carried out over the course of six weeks in three sessions of 30 minutes each (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session. The resistance-training program was performed with Universal weights.
Study: NCT05355155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar IBI305
Description: Patients received bevacizumab and FOLFOX4 every two weeks
Study: NCT05923515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000197
Description: for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000197
Description: for injection
Study: NCT06479902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core stability exercise
Description: Core stability exercises featured moves such as planks and side planks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Strengthening Exercise
Description: . Diaphragmatic exercises included diaphragmatic breathing in various positions.
Study: NCT06129214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prepectoral
Description: Remove all visible synovium in suprapatellar area under distal quadriceps tendon. All other procedures (Total Knee arthroplasty) are same with no intervention arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subpectoral
Description: No remove any synovium in suparapatellar area under distal quadriceps tendon. All other preocedures are same with experimental arm.
Study: NCT05755126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iatrosedation
Description: Alleviating the anxiety of patients by iatrosedative interview and clinical encounter

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical Therapy
Description: Patients were provided with headphones and a playlist to listen to the music of their choice for 10 minutes
Study: NCT04992247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-MSC
Description: 2, 4 or 6 MSC vials (approximately 15 million cells/vial) will be intravenously infused on Day 0, Day 2, or Day 4 depending on assignment to treatment group.~Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4~Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4~Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2~Group D: 2 MSC vials infused on D0, D2 and D4

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.
Study: NCT05475639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Axillary Diclofenac phonophoresis
Description: axillary diclophenac phonophoresis (voltaren gel) will be received three times per week for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric facilitation
Description: Post isometric facilitation exercise will be received three times per week for four weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Traditional physiotherapy will be received three times per week for four weeks
Study: NCT05989425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day.
Study: NCT05902065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVR Treadmill training with C-Mill
Description: The protocol will include three sessions per week for 8 weeks of gait training using C-Mill with AVR applications. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. The patient will be supervised by a physical therapist and asked not to use lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance. Progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'; progression in difficulty: the protocol has 5 levels for each AVR application, and the transition among levels will be set at 80% success achievement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treadmill training with C-Mill
Description: The protocol will include three sessions per week for 8 weeks of gait training using C-Mill without AVR applications, walking on the treadmill. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. All sessions will be supervised by a physical therapist, who will give guidance and standardized cues on walking patterns (e.g., step length). The patient will be asked not to use the lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance: progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'.
Study: NCT05545917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: APP care
Description: The experimental arm will receive advanced physiotherapy care (APP) care. Patients will be independently managed (assessment and intervention) by a PT. The PT will make a diagnosis and initiate an intervention plan (e.g. education and exercise). If relevant, the PT will make recommendations for medical imaging tests or medication. PTs will also recommend the proper discharge from the emergency department (ED), such as hospitalization, discharge without medical consultation/follow-up or discharge with a medical follow-up or rehabilitation in an outpatient setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - Usual physician care
Description: The control arm will receive usual ED physician care delivered only by an ED physician. This will include independent assessment, treatment and discharge by an ED physician with no physiotherapy within the ED but physician's referral to outpatient physiotherapy or other professionals/medical specialists will be possible; overall care offered by the ED physician will not be standardized but will be systematically documented.
Study: NCT05859698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: Valbenazine capsules for oral administration
Study: NCT05362201

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic position of the anterior repositioning splints
Description: the ADDWR paricipants will be allocated into 2 grounps and treated with anterior repositioning splints determined by traditional and digitial method respectively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic position of the anterior repositioning splints
Description: the ADDWR paricipants will be allocated into 2 grounps and treated with anterior repositioning splints determined by traditional and digitial method respectively.
Study: NCT05811364

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
Description: Treatment of target lesions in the common and/or external iliac arteries by stenting with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent
Description: Treatment of target lesions in the common and/or external iliac arteries by stenting with a commercially available bare metal stent that is approved for treatment of the disease.
Study: NCT06235437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASD141
Description: Subjects will receive one of 4 dose levels of ASD141.
Study: NCT05158816

Intervention type: PROCEDURE
Intervention: ECMO
Description: Patients undergoing extracorporeal membrane oxygenation
Study: NCT06106750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary duct cutting
Description: Endoscopic retrograde cholangiopancreatography and endoscopic nasobiliary duct placement and drainage are conducted first. Upon achieving a postoperative state marked by satisfactory nasobiliary duct drainage and overall patient stability, the procedure entails the employment of endoscopic scissors. The tools are applied to make an incision on the external segment of the nasobiliary duct, positioned beyond the aperture of the primary duodenal papilla. Then extracting the severed nasobiliary duct and retaining the portion inside the duct.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral plastic stent
Description: Standard protocol for the placement of bilateral biliary plastic stents in the management of malignant hilar biliary tract stenosis
Study: NCT06386406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP insole
Description: The patients will have to wear the TAP insole when walking during the everyday life activities.~This plantar insole is not a custom-made insole but a pre-confectioned one because designed according to two parameters: shoe size and gender.
Study: NCT05167071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM4003
Description: Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.
Study: NCT04779177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 42 mg
Description: Lumateperone 42 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 28 mg
Description: Lumateperone 28 mg, oral administration
Study: NCT03998735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal Snuff (Smokeless Tobacco)
Description: 4 levels of \[D4\]nornicotine in herbal snuff

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal Snuff (Smokeless Tobacco)
Description: 4 levels of \[D4\]nornicotine in herbal snuff

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal Snuff (Smokeless Tobacco)
Description: 4 levels of \[D4\]nornicotine in herbal snuff

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herbal Snuff (Smokeless Tobacco)
Description: 4 levels of \[D4\]nornicotine in herbal snuff
Study: NCT04219189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaping condition
Description: Participants will be asked to use a JUUL device to vape 20 puffs over 20 minutes. Participants will use JUUL pods with \~5% nicotine by weight. The anticipated amount of nicotine that will be absorbed with 20 puffs is approximately 1.6 mg, which is equal to approximately 1.5 cigarettes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaping condition
Description: Participants will be asked to use a JUUL device to vape 20 puffs over 20 minutes. Participants will use JUUL pods with \~5% nicotine by weight. The anticipated amount of nicotine that will be absorbed with 20 puffs is approximately 1.6 mg, which is equal to approximately 1.5 cigarettes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control condition
Description: Participants will have access to an uncharged JUUL device with an empty pod for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control condition
Description: Participants will have access to an uncharged JUUL device with an empty pod for 20 minutes.
Study: NCT06265311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IDUS examination
Description: for patients with high risks of bile duct stones recurrence using IDUS during ERCP
Study: NCT04730011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short and Intensive Treatment
Description: Intensive Treatment Week with behavioural psychotherapy
Study: NCT05534815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employment-based abstinence reinforcement
Description: Participants will earn stipends for working with the employment specialist and wage supplements for working in a community job, but the stipends and wage supplements will depend on providing drug-free urine samples.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employment-based abstinence reinforcement
Description: Participants will earn stipends for working with the employment specialist and wage supplements for working in a community job, but the stipends and wage supplements will depend on providing drug-free urine samples.
Study: NCT06228794

Intervention type: OTHER
Intervention: Peripheral blood test
Description: We will draw 2-5 mL of peripheral blood and utilize multiparameter flow cytometry to measure the level of circulating plasma cells.
Study: NCT05093868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrographic Flow Mapping
Description: Electrographic Flow Mapping will be collected
Study: NCT05716048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KF-mSMT Plus Aerobic Exercise Training
Description: Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KF-mSMT Plus Stretching Exercise Training
Description: Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
Study: NCT05094427

Intervention type: PROCEDURE
Intervention: Preoperative fluoroscopically-guided dorsal ramus block placed by the operative neurosurgeon
Description: Patients received bupivicaine injections delivered via 22-gauge spinal needle to the junction of the facet and transverse process or ala at multiple spinal levels (2.5-5 cc per injection of 0.25% or 0.5% bupivacaine).
Study: NCT05493631

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MG1113
Description: MG1113 subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MG1113
Description: MG1113 subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MG1113
Description: MG1113 subcutaneous (SC) injection
Study: NCT06044987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans Obturator Tape Procedure (TOT)
Description: Done under Spinal anesthesia in the dorsal lithotomy position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans Obturator Tape Procedure (TOT)
Description: Done under Spinal anesthesia in the dorsal lithotomy position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystocele Repair
Description: Done under Spinal anesthesia in the dorsal lithotomy position..
Study: NCT05971589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LM103
Description: Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
Study: NCT06572098

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex decongestive therapy
Description: Complex decongestive therapy consists of 4 phases. It will be performed by a lymphedema physiotherapist trained in Complex Decongestive Physiotherapy. Complex decongestive therapy consists of manual lymph drainage, skin care, multilayer bandaging and therapeutic exercises.
Study: NCT05138562

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: 4 x placebo capsules, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: TU2670 320mg
Description: 320mg (80mg x 4), QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: TU2670 240mg
Description: 240mg (80mg x 3 + placebo x 1), QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: TU2670 120mg
Description: 120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
Study: NCT05297682

Intervention type: DEVICE
Intervention: anesthesia with propofol
Description: General anesthesia with propofol

Intervention type: DEVICE
Intervention: anesthesia with propofol
Description: General anesthesia with propofol
Study: NCT05186480

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Neo Mune
Description: Neo-mune is a nutritional formula used in enteral feeding for critically ill patients. It's mainly indicated in cases of malnutrition, post surgeries and traumas and immunocompromisation.~Its composition:~Composition in approximate %w/w Maltodextrin 42.44% Sodium caseinate 18.25% MCT oil 6.28% Arginine 5.21% Polydextrose 4.00% Corn oil 3.48% Glutamine 2.61% Fish oil 2.32% Minerals 1.96% Vitamins 0.86% Artificial flavor (vanilla)
Study: NCT05604417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAZEMETOSTAT
Description: Dosage and treatment timings per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAZEMETOSTAT
Description: Dosage and treatment timings per protocol